Get the Stockscreener App
110.05
5.87%
6.10
After Hours:
110.05
Blueprint Medicines Corp stock is traded at $110.05, with a volume of 931.34K.
It is up +5.87% in the last 24 hours and up +14.07% over the past month.
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.
See More
Previous Close:
$103.95
Open:
$105.87
24h Volume:
931.34K
Relative Volume:
1.36
Market Cap:
$6.89B
Revenue:
$434.41M
Net Income/Loss:
$-128.05M
P/E Ratio:
-52.16
EPS:
-2.11
Net Cash Flow:
$-250.52M
1W Performance:
+25.87%
1M Performance:
+14.07%
6M Performance:
-3.77%
1Y Performance:
+38.64%
1-Day Range:
$104.73
$110.28
1-Week Range:
$90.23
$110.28
52-Week Range:
$72.24
$121.90
Blueprint Medicines Corp Stock (BPMC) Company Profile
Name
Blueprint Medicines Corp
Sector
Industry
Phone
617-374-7580
Address
45 SIDNEY STREET, CAMBRIDGE, MA
Compare BPMC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BPMC
Blueprint Medicines Corp
|
110.05 | 6.89B | 434.41M | -128.05M | -250.52M | -2.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Blueprint Medicines Corp Stock (BPMC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-14-24 | Initiated | JP Morgan | Overweight |
| Oct-24-24 | Initiated | UBS | Neutral |
| May-14-24 | Initiated | Stephens | Overweight |
| May-06-24 | Upgrade | Leerink Partners | Underperform → Market Perform |
| Oct-27-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Aug-21-23 | Reiterated | Needham | Buy |
| Jul-31-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jun-05-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Jan-03-23 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Dec-14-22 | Initiated | Needham | Buy |
| Nov-02-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Sep-14-22 | Initiated | Berenberg | Buy |
| Jul-08-22 | Initiated | Oppenheimer | Outperform |
| Jun-27-22 | Initiated | Wells Fargo | Underweight |
| Jun-10-22 | Downgrade | Citigroup | Neutral → Sell |
| Jun-01-22 | Upgrade | Jefferies | Hold → Buy |
| Mar-01-22 | Initiated | Citigroup | Neutral |
| Feb-17-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jan-25-22 | Upgrade | Stifel | Hold → Buy |
| Nov-19-21 | Resumed | Morgan Stanley | Equal-Weight |
| Sep-30-21 | Resumed | Stifel | Hold |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Mar-31-21 | Initiated | Credit Suisse | Neutral |
| Dec-03-20 | Initiated | Stifel | Hold |
| Nov-02-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-02-20 | Downgrade | Jefferies | Buy → Hold |
| Oct-30-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-15-20 | Reiterated | H.C. Wainwright | Buy |
| May-05-20 | Initiated | Barclays | Equal Weight |
| Mar-17-20 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jan-28-20 | Initiated | BMO Capital Markets | Market Perform |
| Jan-27-20 | Initiated | BMO Capital Markets | Market Perform |
| Nov-06-19 | Upgrade | Raymond James | Outperform → Strong Buy |
| Oct-22-19 | Initiated | JMP Securities | Mkt Outperform |
| Oct-03-19 | Initiated | H.C. Wainwright | Buy |
| Sep-12-19 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-29-19 | Initiated | Piper Jaffray | Neutral |
| Aug-15-19 | Resumed | Raymond James | Mkt Perform |
| Jul-18-19 | Initiated | Deutsche Bank | Buy |
| May-23-19 | Resumed | Goldman | Buy |
| Apr-03-19 | Initiated | Morgan Stanley | Overweight |
| Sep-25-18 | Initiated | Leerink Partners | Outperform |
| Dec-11-17 | Reiterated | Goldman | Buy |
View All
Blueprint Medicines Corp Stock (BPMC) Latest News
Assenagon Asset Management S.A. Has $8.49 Million Stock Position in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Empirical Asset Management LLC Acquires Shares of 26,921 Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
JMP Securities Reaffirms Market Outperform Rating for Blueprint Medicines (NASDAQ:BPMC) - Defense World
FY2027 Earnings Estimate for BPMC Issued By Leerink Partnrs - Defense World
FY2027 Earnings Forecast for BPMC Issued By Leerink Partnrs - MarketBeat
Blueprint Medicines (NASDAQ:BPMC) vs. CV Sciences (OTCMKTS:CVSI) Financial Contrast - Defense World
Insider Selling: Blueprint Medicines Co. (NASDAQ:BPMC) Director Sells 5,000 Shares of Stock - MarketBeat
Ariel Hurley Sells 2,250 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) Stock - MarketBeat
Blueprint Medicines officer Hurley Ariel sells $225,000 in stock By Investing.com - Investing.com South Africa
Blueprint Medicines director Jeffrey Albers sells $511,400 in stock - Investing.com
Blueprint Medicines' SWOT analysis: stock surges on Ayvakit success - Investing.com
Blueprint Stock Soars 18% on Encouraging 2025 Growth Strategy - MSN
Blueprint Medicines (NASDAQ:BPMC) Shares Gap UpTime to Buy? - MarketBeat
Zacks Industry Outlook Highlights Incyte, BioMarin, Exelixis, Halozyme and Blueprint Medicines - Yahoo Finance
Blueprint Medicines Corporation Updates Corporate Presentation at J.P. Morgan Healthcare Conference - Defense World
Blueprint Medicines (BPMC) Stock Jumps 18.2%: Will It Continue to Soar? - Yahoo Finance
Blueprint Medicines’ (BPMC) Buy Rating Reaffirmed at Needham & Company LLC - Defense World
Blueprint Medicines (NASDAQ:BPMC) Receives “Outperform” Rating from Wedbush - Defense World
Blueprint Medicines shares surge on growth strategy and upbeat trial data - Investing.com
Blueprint Medicines Highlights 2024 Achievements and Future Growth - TipRanks
Blueprint Medicines Surges Over 10% as 2025 Growth Strategy Ignites Investor - Yahoo Finance
Intra-Cellular Therapies, Standard BioTools, SI-BONE And Other Big Stocks Moving Higher On Monday - Benzinga
Blueprint Medicines' (BPMC) Outperform Rating Reiterated at Wedbush - MarketBeat
Blueprint Medicines (NASDAQ:BPMC) Earns "Buy" Rating from Needham & Company LLC - MarketBeat
Blueprint Medicines Provides 2025 Outlook and Highlights Strategy for Continued Growth - PR Newswire
Diversified Trust Co Sells 8,258 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
NUT Midline Carcinoma Treatment Market Research Report 2023-2024 & 2034: Market Forecast by Treatment, Route of Administration, and End-User Across 5 Regions and 17+ Countries - GlobeNewswire Inc.
Blueprint Medicines (NASDAQ:BPMC) Stock Price Up 5.7%Still a Buy? - MarketBeat
Stifel maintains Buy rating and $155 target on Blueprint Medicines stock - Investing.com
Korea's only RET inhibitor, Retevmo, seeks insurance coverage again - KBR
Principal Financial Group Inc. Has $1.02 Million Holdings in Blueprint Medicines Co. (NASDAQ:BPMC) - Defense World
Principal Financial Group Inc. Sells 47,153 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines Co. (NASDAQ:BPMC) Receives $123.33 Consensus Target Price from Brokerages - MarketBeat
Blueprint Medicines Co. (NASDAQ:BPMC) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
Blueprint Medicines’ (BPMC) “Overweight” Rating Reaffirmed at Stephens - Defense World
What Analysts Are Saying About Blueprint Medicines Stock - Benzinga
Blueprint Medicines (NASDAQ:BPMC) Receives Overweight Rating from Stephens - MarketBeat
Blueprint Medicines to Report Third Quarter 2024 Financial Results on Wednesday, October 30, 2024 - Quantisnow
Sanctuary Advisors LLC Invests $202,000 in Blueprint Medicines Co. (NASDAQ:BPMC) - Defense World
Blueprint Medicines to Present at Upcoming Investor Conferences - Longview News-Journal
First Week of BPMC February 2025 Options Trading - Nasdaq
Blueprint Medicines director Jeffrey Albers sells $1.35 million in stock By Investing.com - Investing.com Australia
Blueprint Medicines director Jeffrey Albers sells $1.35 million in stock - Investing.com India
Insider Sell: Christina Rossi Sells Shares of Blueprint Medicines Corp (BPMC) - GuruFocus.com
Blueprint Medicines COO Christina Rossi sells $218,098 in shares By Investing.com - Investing.com Australia
Blueprint Medicines COO Christina Rossi sells $218,098 in shares - Investing.com
Blueprint Medicines Co. (NASDAQ:BPMC) Director Jeffrey W. Albers Sells 15,000 Shares - MarketBeat
Insider Selling: Blueprint Medicines Co. (NASDAQ:BPMC) COO Sells 2,274 Shares of Stock - MarketBeat
Blueprint Medicines' SWOT analysis: stock's potential in precision oncology By Investing.com - Investing.com Australia
Blueprint Medicines (NASDAQ:BPMC) Shares Down 3.6%What's Next? - MarketBeat
Blueprint Medicines Corporation Seeks Validation of 2024 Stockholder Actions Through Section 205 Action - Defense World
Blueprint Medicines Corp Stock (BPMC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.65%
4.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):